AyuVis Research, Inc.

AyuVis designs and develops novel, small molecule immunotherapies to prevent and treat inflammatory and infectious diseases by modulating the innate immune system. Our lead series of drug candidates are based on a platform technology of macrophage modulation. The lead drug candidate, AVR-48, with an excellent safety profile is at the IND-stage and has been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for the lead indication, the prevention of bronchopulmonary dysplasia in preterm infants. Follow-on high unmet need respiratory applications include acute respiratory distress syndrome (ARDS), Multi-Drug Resistant ventilator-associated pneumonia, and ventilator-associated lung injury. Other therapeutic areas that can be addressed by our drug candidates include ocular, renal, skin, intestinal diseases, and complicated infections (sepsis).

AyuVis’ technology is protected by two approved and four pending patents and has five peer-reviewed publications in scientific journals. AyuVis has received 3 NIH SBIR grants and more are under review. The company has raised $5M in seed funding and is currently raising a Series A equity round of $16M to fund Phase 1 safety and Phase 2a early PoC clinical trials to lift the company to clinical-stage and advance the pipeline. Current strategic discussions with large pharmaceutical companies are in progress.